Evox Therapeutics Ltd collaborates with Rett Syndrome Research Trust to evaluate its ExoEdit® exosome-based platform for developing a potential gene editing therapy targeting Rett syndrome.
Evox Therapeutics Ltd has announced a new strategic collaboration with the Rett Syndrome Research Trust (RSRT) to evaluate the potential of its proprietary ExoEdit® gene editing platform as a novel therapeutic approach for Rett syndrome. The partnership represents a significant step forward in the effort to overcome one of the most pressing challenges in neurogenetic medicine: safely and effectively delivering gene editing tools to the central nervous system (CNS).
Advancing a New Frontier in Gene Editing Delivery
Evox is a biotechnology company focused on developing innovative therapies for genetically driven neurodegenerative diseases. At the heart of its platform is ExoEdit®, an advanced exosome-based delivery technology designed to transport gene editing cargo precisely to target tissues, including the brain. Exosomes are naturally occurring extracellular vesicles that play a key role in cell-to-cell communication. By engineering these vesicles to carry therapeutic payloads, Evox aims to create a non-viral, potentially safer and more efficient method of delivering gene editing tools.
The collaboration with RSRT will assess whether ExoEdit® can be used to enable gene editing treatments for Rett syndrome, a severe neurodevelopmental disorder that primarily affects girls and is most commonly caused by mutations in the MECP2 gene. These mutations disrupt the normal function of methyl-CpG-binding protein 2 (MeCP2), a critical regulator of gene expression in the brain. The resulting dysfunction leads to a wide range of debilitating symptoms, including loss of motor skills, impaired speech, seizures, breathing irregularities, and cognitive challenges.
The Unmet Need in Rett Syndrome
Rett syndrome is a devastating condition that typically emerges in early childhood after an initial period of seemingly normal development. Affected children often lose acquired language and motor abilities between 6 and 18 months of age. Over time, the disorder profoundly impairs mobility, communication, and independence. Many patients require lifelong, around-the-clock care and support from specialized multidisciplinary medical teams to manage complex, multi-system complications.
While advances in symptomatic management have improved quality of life, there remains no cure that addresses the underlying genetic cause of the disease. Gene editing has long been viewed as a promising strategy for Rett syndrome because it offers the possibility of correcting the mutations in MECP2 directly at the DNA level. In theory, repairing or restoring proper gene function could halt disease progression and potentially reverse symptoms—even after onset.
However, despite the transformative promise of gene editing technologies such as CRISPR-based systems, delivering these molecular tools to the brain in a safe, controlled, and widespread manner remains a major hurdle. Viral vectors, commonly used in gene therapy, can raise concerns related to immunogenicity, limited cargo capacity, and potential off-target effects. Moreover, achieving broad distribution throughout the brain is especially challenging.
Exosome-Based Delivery: A Potential Solution
Evox’s ExoEdit® platform seeks to address these obstacles through the use of engineered exosomes. Because exosomes are naturally derived and capable of crossing biological barriers, including the blood-brain barrier, they may offer advantages over traditional viral delivery systems. By loading gene editing machinery into these vesicles, Evox aims to enable targeted, efficient delivery to neural tissues while minimizing safety risks.
According to Per Lundin, PhD, Co-founder and Chief Executive Officer of Evox, gene editing holds the potential to correct the mutations responsible for Rett syndrome and possibly reverse symptoms even after the disease has manifested. However, he emphasized that safe and efficient CNS delivery remains the key challenge that must be solved to unlock this potential.
Lundin noted that ExoEdit® is designed specifically to help gene editing medicines reach the brain safely and effectively. If successful, the platform could make it feasible to address the root causes of devastating neurological diseases, including Rett syndrome, by directly correcting pathogenic mutations at their source.
The Role of RSRT in Driving Innovation
The Rett Syndrome Research Trust has played a pivotal role in accelerating research toward disease-modifying therapies. Founded by Monica Coenraads, whose adult daughter lives with Rett syndrome, RSRT is a nonprofit organization dedicated to advancing high-impact research with a clear path to clinical translation. The organization has been instrumental in supporting gene therapy and gene editing initiatives aimed at correcting MECP2 mutations.
Monica Coenraads highlighted that non-viral delivery to the brain has long been one of the principal obstacles to establishing gene editing as a viable therapeutic strategy for Rett syndrome. She expressed optimism that Evox’s exosome-based approach could provide a breakthrough solution.
Coenraads stated that RSRT sees strong potential in ExoEdit® to efficiently and safely deliver gene editing cargo throughout the brain. She and her colleagues are enthusiastic about the collaboration and eager to evaluate the study’s findings, which could open the door to a new clinical pathway for patients living with Rett syndrome.
Laying the Foundation for a Broader Development Program
If the feasibility study proves successful, the collaboration could pave the way for an expanded preclinical development program focused on Rett syndrome. The ultimate goal would be to create an exosome-enabled gene editing therapy capable of addressing the majority of Rett cases caused by MECP2 mutations.
Such a development would represent a major milestone not only for Rett syndrome but also for the broader field of neurogenetic disorders. Demonstrating effective non-viral gene editing delivery to the CNS could have far-reaching implications for a wide array of neurological diseases driven by genetic mutations.
The collaboration reflects a growing trend in biotechnology toward combining innovative delivery technologies with powerful gene editing tools to overcome longstanding therapeutic barriers. By leveraging the complementary strengths of Evox’s platform and RSRT’s deep expertise in Rett syndrome research, the partnership aims to translate cutting-edge science into tangible clinical progress.
A Step Toward Transformative Therapies
For families affected by Rett syndrome, the promise of a treatment that targets the underlying genetic cause offers hope beyond symptom management. While significant scientific and regulatory steps remain ahead, this collaboration represents a meaningful stride toward making gene editing a viable therapeutic reality for patients.
Evox’s work with RSRT underscores the importance of collaboration between biotechnology innovators and mission-driven research organizations. Together, they are addressing one of the central challenges in modern medicine: delivering advanced genetic therapies precisely where they are needed most.
As the feasibility studies progress, the scientific community and Rett syndrome families alike will be watching closely. Success could mark the beginning of a new era in which exosome-based gene editing transforms the treatment landscape for neurodevelopmental disorders, bringing renewed hope to patients and caregivers worldwide.
